Tokyo, Japan, October 27th, 2026, Chainwire

Fort Lauderdale, Florida, United States, October 26th, 2026, FinanceWire

New York, United States, October 26th, 2026, Chainwire

Eli Lilly (NYSE:LLY), Novo Nordisk (NYSE:NVO), AstraZeneca (NASDAQ:AZN), and Roche (OTCQX:RHHBY) are among the pharmaceutical leaders investing billions of dollars in new manufacturing capacity as obesity medicines emerge as one of the industry's biggest long-term growth markets. With four major U.S. manufacturing projects totaling $17.1 billion, drugmakers are positioning themselves to meet expanding demand for treatments that could generate trillions of dollars in cumulative sales over the next two decades.